文献速递甲状腺与颈部外科围术期管理与 ERAS

手术方式与肿瘤大小对胸腺瘤结局的影响:70例回顾性分析

Surgical approach and tumor size influence outcomes in thymoma: a retrospective analysis of 70 cases.
PubMed 文献 · Surg Endosc · 2025-12-09

该研究回顾性分析2001至2023年间70例Masaoka I-II期胸腺瘤患者,按手术方式分为开放手术20例与微创手术50例(视频辅助或机器人辅助),并以5厘米和6厘米为界按CT及标本测量分层肿瘤大小,采用倾向性评分匹配比较围术期结局。结果显示微创手术术中出血更少、引流时间更短、住院时间更短,且无中转开放,匹配后获益仍存在;微创组内肿瘤≥5厘米未显著影响手术时间、出血或恢复,全队列仅见1例复发。

要点

  • 微创手术较开放手术出血少、引流短、住院短,且无中转开放。
  • 微创组内肿瘤≥5厘米未显著影响手术时间、出血与恢复。
  • 长期肿瘤学有效性尤其胸膜播散与晚期复发仍需多中心前瞻性研究确认。

核心结论

  • 微创手术较开放手术提供更优的短期围术期结局,对经选择的较大胸腺瘤患者似可行。
  • 微创手术的长期肿瘤学有效性尤其胸膜播散与晚期复发尚待多中心前瞻性研究证实。

研究设计与样本

  • 回顾性分析2001至2023年70例Masaoka I-II期胸腺瘤患者,开放手术20例、微创手术50例(视频或机器人辅助)。
  • 按术前CT与标本测量并以5厘米和6厘米为阈值分层肿瘤大小,采用倾向性评分匹配比较围术期结局。

主要发现

  • 微创手术较开放手术术中出血更少、引流时间更短、住院时间更短,且无中转开放,匹配后获益仍存在。
  • 微创应用逐步扩展至≥5厘米肿瘤,后期阶段围术期结局改善。
  • 微创组内肿瘤≥5厘米未显著影响手术时间、出血或恢复;以6厘米为界 Exploratory 分析显示总体结局相当。
  • 全队列肿瘤学事件罕见,仅观察到1例复发。

临床怎么用

  • 对Masaoka I-II期胸腺瘤可优先考虑微创入路以改善短期围术期结局。
  • 较大肿瘤(≥5厘米)在经选择患者中微创仍可考虑,但需个体化评估。
  • 术后需关注长期肿瘤学随访,尤其胸膜播散与晚期复发。

局限性

  • 为单中心回顾性分析,样本量70例。
  • 长期肿瘤学结局数据有限,仅1例复发,需多中心前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive surgery (MIS) has become increasingly applied in thymoma, but its feasibility for large tumors remains contested. METHODS: We retrospectively reviewed 70 patients, treated between 2001 and 2023, with Masaoka stage I-II thymomas. Patients were stratified according to surgical approach-open surgery (OP, n = 20) or MIS (video- or robot-assisted, n = 50)-and tumor size using both preoperative CT and specimen measurements with 5- and 6 cm thresholds. Perioperative outcomes were compared using propensity score matching (PSM). RESULTS: MIS was associated with less intraoperative blood loss, shorter drainage duration, and shorter hospital stay compared with OP, without conversions to OP. These benefits persisted after PSM. The use of MIS gradually expanded to include tumors ≥ 5 cm, with perioperative outcomes improving in a later phase. Within the MIS cohort, tumor size ≥ 5 cm did not significantly affect operative time, blood loss, or recovery. Exploratory analyses using a 6 cm cutoff showed comparable overall outcomes. Oncologic events were rare, with only one recurrence observed in the entire cohort. CONCLUSIONS: MIS offers superior short-term perioperative outcomes compared with OP and appears feasible for selected patients with large thymomas. However, its long-term oncologic validity-particularly regarding pleural dissemination and late recurrence-requires confirmation in multicenter prospective studies.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Hanaoka J, Hayashi K, Yoden M, et al. Surgical approach and tumor size influence outcomes in thymoma: a retrospective analysis of 70 cases. Surg Endosc. 2025. PMID: 41366574. doi:10.1007/s00464-025-12435-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。